Innovation is the driving force behind our strong research and development pipeline.
With vaccine candidates in preclinical and clinical development, we are supported by a range of patented technologies such as our PER.C6® human cell line technology which could enable faster and more cost-effective discovery, development and production of a range of potentially transformational vaccines and monoclonal antibodies.
|PER.C6® Technology||AdVac® Technology|
|A comprehensive package of tools and know-how based on our PER.C6® human cell line technology. It provides a cost-effective manufacturing system for high-yield, large-scale production of vaccines and monoclonal antibodies. It is especially useful for vaccine manufacturing that requires the production of hard-to-grow viruses and holds the key to making such vaccines affordable for the whole world.||A technology based on the development and production of adenovirus vectors (gene carriers). It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening infectious diseases.|